Biosimilar Launches Depend Mostly On Patents After Supreme Court Ruling
Executive Summary
US high court says biosimilar sponsors do not have to wait until after FDA approval to start countdown clock for marketing, but patent litigation may impede launches.
You may also be interested in...
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.
EU’s CHMP Expected To OK Another Biosimilar Humira
The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha Humira on June 23. Numerous other biosimilar developers have biosimilar adalimumabs under development in a bid to break into the $16bn market for the world’s top-selling drug.